Flexion, a specialty pharmaceutical company with Phase 2 assets, is developing a portfolio of best in class intra-articular (IA), sustained release (SR), novel medicines for the treatment of musculoskeletal diseases. The first area of focus is Osteoarthritis (OA), a disease that affects more than 27 million adults in the U.S and is the leading cause of disability. The market for IA injection products is large, well established, and growing, but existing products have many limitations. OA patients are in substantial need of new therapies that are both safe and confer lasting pain relief. Our best in class portfolio of IA medicines represent a new paradigm for the treatment of OA.
Recent & Upcoming Presentations
April 22-25, 2013: BIO-Chicago Presenting Company